PHST Pharsight Corp (MM)

Dr. Farkad Ezzet Will Present on the Strategic Value of Literature Modeling to Assess Disease Progression and Drug Attributes in Clinical Development MOUNTAIN VIEW, Calif., June 17 /PRNewswire-FirstCall/ -- Pharsight Corporation (NASDAQ:PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Farkad Ezzet, Ph.D., senior scientist, Pharsight Strategic Consulting Services, has been invited to speak to members of the biotechnology and pharmaceutical industries attending the 2008 AAPS National Biotechnology Conference. The Congress will be held at the Metro Toronto Convention Center in Toronto, Canada from June 22-25, 2008. Dr. Ezzet will present on June 24, joining other leading industry experts in a roundtable session on the utilization of disease progression models in clinical drug development. Dr. Ezzet's presentation, entitled "The Role of Literature-Based Disease Progression Models to Support Knowledge Management and Decision-Making in Clinical Drug Development," will describe how model-based approaches that incorporate public-source data from the scientific literature can provide quantitative insights into disease progression and predictive assessments of a new drug candidate's likely product profile versus competing treatments. Dr. Ezzet's presentation will feature an illustrative case study for the treatment of obesity, and will also cover important considerations for using literature-based modeling approaches to enhance strategic decision-making in drug development. "Literature-based models provide a quantitative assessment of the competitive landscape and offer a framework to address important clinical development program questions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Public domain information and data can be leveraged to develop candidate disease models, to measure the performance of established treatments across target therapeutic areas, and to help predict the likely clinical profile of early-stage development compounds. Pharsight is pleased to participate at the AAPS roundtable session, and we look forward to sharing our perspective with industry colleagues on the strategic use of modeling and simulation to enhance drug development decision-making." Further information can be found at http://www.aapspharmaceutica.com/meetings/biotec/bt08. About Pharsight Corporation Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products. Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com/. Registered Trademarks and Trademarks Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations. DATASOURCE: Pharsight Corporation CONTACT: Media, Steve DiMattia or Donald Takaya, +1-646-201-5445, or Investors, Douglas Sherk or Matthew Selinger, +1-415-896-6820, all of EVC Group for Pharsight Corporation Web site: http://www.pharsight.com/ http://www.aapspharmaceutica.com/meetings/biotec/bt08

Copyright